Messenger-RNA platforms that encode a patient's neoantigens and are translated into protein in vivo — the modality behind Moderna/Merck's mRNA-4157 and BioNTech's autogene cevumeran.
Moderna is leveraging the Phase 3 success of its personalized mRNA cancer vaccine to expand its pipeline into universal cancer vaccines and in-body immune cell modification technologies. A common-antigen targeted therapy requiring no patient-specific manufacturing process, along …
The item highlights personalized mRNA cancer vaccines as a potential therapeutic direction, citing 2.1 million new U.S. cancer cases and 626,000 cancer deaths this year from the American Cancer Society. It identifies Moderna and Merck as a leading combination approach pairing an immunotherapy drug with an experimental made-to-order mRNA cancer vaccine, and says late-stage studies have shown success in directing the immune system toward tumor-specific mutations. The implication is that the field is moving toward late-stage, commercialized personalized vaccines, but the item also notes conflicting U.S. official signals about mRNA technology, safety, and potential.
Moderna and Merck reported that their personalized mRNA cancer vaccine mRNA-4157 met its primary endpoint in the Phase 3 INTerpath-001 trial, which enrolled 1,137 high-risk melanoma patients after complete surgical resection. The vaccine combined with Keytruda produced statistically significant improvements in recurrence-free survival and distant metastasis-free survival versus Keytruda monotherapy. The result added more than $50 billion in combined market value to the two companies, with Moderna’s stock rising 177% and adding about $44 billion, and is pushing oncology sequencing and diagnostics into the capital-markets spotlight. It also heightens speculation around Tempus AI’s Personalis bid and rivalry in the sequencing sector.
Log in here to read the desired article. BioNTech and Genentech have terminated a Phase 2 trial of their personalized mRNA cancer vaccine autogene cevumeran in colorectal cancer after more deaths occurred in the vaccine arm than among patients under observation. The setback comes…
The development of cancer immunotherapy is increasingly moving beyond broadly administered immune checkpoint blockade toward strategies designed around the molecular characteristics of an individual patient’s tumor. A major milestone in this direction has now been reported. On Au…
Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma. The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination …
Matteo S. Carlino, MD, PhD, FRACP, discussed V940 plus pembrolizumab data, safety, and administration in resected melanoma. CancerNetwork® spoke with Matteo S. Carlino, MD, PhD, FRACP, a medical oncologist at Westmead and Blacktown Hospitals, a faculty member at Melanoma Institut…
Ugur Sahin, Professor for Translational Oncology and Immunology at University Medical Center Mainz, shared a post on LinkedIn: “Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes. It lacks the three receptors (ER/PR/HER2) that enable targete…
Matteo S. Carlino, MD, PhD, FRACP, explains how the individualized neoantigen therapy V940 is designed and delivered in melanoma. Matteo S. Carlino, MD, PhD, FRACP, a medical oncologist at Westmead and Blacktown Hospitals, a faculty member at Melanoma Institute Australia, and a c…
Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma. The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination …
Personalized mRNA vaccines are showing promise as a new way to fight cancer, particularly melanoma. The vaccines are designed around mutations unique to a patient’s tumor, helping the immune system target cancer cells. While recent trial results are encouraging, researchers say m…
Moderna and Merck say their personalized mRNA cancer vaccine significantly reduced the risk of melanoma returning or spreading. Get up-to-the-minute news sent straight to your device. Account processing issue - the email address may already exist Must be at least 8 characters, no…
Test your knowledge with our new weekday mini crossword Matthew Herper covers medical innovation — both its promise and its perils. Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as…
On August 19, 2026, a single piece of clinical data sent Moderna's stock soaring 177% in one day—one of the largest single-day gains for an S&P 500 constituent in more than two decades. The personalized mRNA cancer vaccine intismeran autogene, co-developed by Moderna and Merck, m…
By The ASCO Post Staff Posted: 8/21/2026 10:29:00 AM Last Updated: 8/21/2026 9:47:23 AM Advertisement Merck and Moderna, Inc. have announced positive topline results from the phase III INTerpath-001 trial (ClinicalTrials.gov identifier NCT05933577) evaluating adjuvant treatment w…
NTxscribe CORE automates mRNA amplification of patient-derived tumor transcriptome, preserving full-length range of each patient’s tumor sequences in a personalized cancer vaccine workflow that is now dosing patients RIO RANCHO, N.M.--(BUSINESS WIRE)--NTx Bio, a leader in next-ge…
The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a new avenue of treatment, but the available evidence is still limited. Interim data from a large trial showed the experimental vaccine, when combined with M…
The experimental mRNA vaccine successfully cleared phase 3 clinical trials, the last step necessary before it can be approved by the FDA. An experimental mRNA cancer vaccine prevented the return and spread of melanoma, the deadliest form of skin cancer, in a large clinical trial,…
Merck and Moderna report positive phase III results for intismeran in melanoma, as The Medicine Maker revisits how cancer vaccines work and the challenges still facing the field A personalized mRNA cancer vaccine has delivered the first positive phase III readout for an individua…
Loizos Loizou, Head of Cyprus International Action Plan for Children with Cancer at ELPIDA Foundation for Children with Cancer, shared on LinkedIn: High-Risk Melanoma, Important New Hope: Personalized Therapeutic mRNA Vaccine. Melanoma is a particularly aggressive and dangerous s…
Intismeran autogene, an individualized neoantigen therapy, makes history on Wall Street as well as within the industry following its first positive Phase III data in a form of melanoma Investors of Merck & Co. (NYSE: MRK) and Moderna (Nasdaq: MRNA) were the most obvious—but not t…
Stéphane Bancel, Founding CEO at Moderna, shared an update from Moderna, on LinkedIn, adding: In 2020, mRNA helped change what was possible in infectious disease, as our teams worked to deliver a COVID-19 vaccine at unprecedented speed, in less than a year. Today, we announced th…
Merck and Moderna announced that their personalized mRNA vaccine regimen successfully passed a large Phase 3 trial, reducing the risk of melanoma return or spread. While the FDA has not yet approved the treatment, the companies note it is the first combination regimen to demonstrate success in potentially extending lifespans for high-risk resected melanoma patients.
In the INTerpath-001 trial, 1,137 patients with resected stage IIB through IV melanoma were randomized to receive Keytruda plus the personalized vaccine or Keytruda plus placebo. The combination arm showed significantly better recurrence-free and distant metastasis-free survival, marking the first positive Phase 3 result for an mRNA-based personalized cancer therapy.
Moderna and Merck announced positive late-stage trial results for a personalized mRNA therapy combined with Keytruda in melanoma patients who had their cancer surgically removed. The companies plan to share full data at upcoming medical meetings, noting that the treatment aims to increase the possibility of cure by intervening early in the disease course.
The INTerpath-001 trial evaluated adjuvant intismeran autogene, an mRNA-based neoantigen therapy tailored to each patient's unique mutational signature, alongside pembrolizumab. Each dose contains synthetic mRNA coding for up to 34 neoantigens derived from the patient's tumor, aiming to activate a targeted anti-tumor immune response in patients with completely resected stage IIB–IV melanoma.
MSD and Moderna reported the first positive Phase III readout for an individualized neoantigen therapy (INT) combined with an mRNA-based cancer therapy. The data shows intismeran autogene plus pembrolizumab can facilitate longer cancer-free survival in completely resected stage IIB-IV melanoma compared to Keytruda alone.
Moderna and Merck announced topline results for their Phase 3 personalized cancer vaccine trial, though full peer-reviewed data is pending. Medical oncologists describe the improvement in recurrence-free and metastasis-free survival as a true breakthrough, noting that success at this level for patient-specific mRNA vaccines addresses previous challenges in the field.
Moderna President Stephen Hoge stated that if regulators approve the personalized cancer vaccine, thousands of patients with high-risk resected melanoma could benefit as soon as next year. The announcement comes as Moderna and Merck seek to establish this mRNA-based neoantigen therapy as a standard adjuvant treatment.
This marks the first positive Phase 3 data for an individualized neoantigen therapy or mRNA-based cancer vaccine. Intismeran delivers mRNA encoding tumor-specific mutations identified from a patient's removed tumor, bundled in lipid nanoparticles to train the immune system against recurrence.
Moderna and Merck’s personalized mRNA vaccine met its main goal in a late-stage melanoma trial when combined with Keytruda. The treatment significantly reduced the risk of high-risk skin cancer returning compared to standard therapy, validating the neoantigen approach in a pivotal setting.
The Phase 3 trial of intismeran autogene involved 1,137 patients with high-risk melanoma whose tumors had been surgically removed. Patients receiving the vaccine plus Keytruda met the primary goal of reducing cancer return and spread compared to Keytruda alone, though detailed statistical data has not yet been released.
STAT’s Adam Feuerstein characterizes 2026 as one of the most consequential years in cancer treatment, citing this mRNA neoantigen success alongside Revolution Medicines’ KRAS drug. The positive late-stage readout signals a major shift in the therapeutic landscape for solid tumors.
The regimen is the first and only combination to demonstrate success in potentially extending melanoma lifespans in Phase 3. Previous Phase 2b data showed a 49% reduction in return and 59% reduction in metastasis, with regulatory review pending full data submission to the FDA.
Moderna’s personalized cancer vaccine has scored a late-stage win, confirming the efficacy of its mRNA platform in preventing melanoma recurrence. This milestone underscores the potential for neoantigen vaccines to become a cornerstone of oncology treatment.
Personalized cancer vaccine shows positive late-stage trial results, reinforcing the strategic value of mRNA-based immunotherapies. The success in melanoma provides a proof-of-concept for broader application across other tumor types.
An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial, the companies announced Wednesday, bringing them one step closer to filing for approval of the treatment option. The mRNA-based shot in combinati…
Moderna and Merck announced positive Phase 3 results for their jointly developed personalized mRNA cancer vaccine in high-risk melanoma patients, marking a historic milestone for mRNA technology in oncology. Combining the vaccine with Keytruda significantly delayed cancer recurre…
A Phase III trial of intismeran autogene, the mRNA-based individualized neoantigen therapy co-developed by Merck (NYSE: MRK) and Moderna (Nasdaq: MRNA), has met both its primary and a key secondary endpoint in patients with completely resected stage IIB-IV melanoma, the companies…
Merck and Moderna’s experimental personalized cancer vaccine has delivered positive results in its first phase three trial, the companies announced Wednesday, moving the treatment closer to potential regulatory approval The mRNA vaccine, combined with Merck’s Keytruda, met the ma…
Moderna and Merck's jointly developed personalized mRNA cancer vaccine has succeeded in suppressing cancer recurrence and metastasis in high-risk melanoma patients in a late-stage clinical trial. This marks the first time a personalized mRNA cancer therapeutic has met its primary…
A recent review identifies mRNA-lipid nanoparticle systems as offering distinct advantages for personalized cancer vaccines, including rapid manufacturing and potent antigen expression. The authors propose combining these delivery platforms with cytokine engineering and T cell modulation to enhance immunogenicity. This synthesis addresses critical challenges in antigen selection and clinical translation that have hindered broader adoption of personalized vaccines.
mRNA platforms are becoming central to neoantigen vaccine development due to their ability to rapidly encode multiple patient-specific epitopes. The field is moving toward clinically meaningful timelines by integrating tumor-normal sequencing, transcriptomic filtering, and algorithmic prioritization, with specific focus on improving less accurate HLA class II predictions.
Merck and Moderna are advancing their individualized neoantigen therapy (INT) platform, leveraging mRNA to train immune systems against patient-specific tumor fingerprints. This commercial partnership highlights the industry's pivot toward 'one medicine for one patient' models, aiming to address genetic uniqueness in cancer care.
Researchers led by Prof. Kazuhiro Kakimi report potent efficacy of an mRNA neoantigen vaccine in gastric cancer models, specifically targeting peritoneal metastasis where current anti-PD-1 therapies fail. Published in Gastric Cancer, this work demonstrates the potential of neoAgs to generate durable responses with fewer off-target effects in difficult-to-treat recurrence scenarios.
Australian entrepreneur Paul Conyngham has launched Gamgee, a startup commercializing AI-designed mRNA vaccines for dogs with ambitions to expand into human therapeutics. The company emerged from viral attention regarding an AI-generated vaccine for the founder's pet, signaling continued market interest in generative AI applications for biotech despite lacking clinical validation data.
Merck and Moderna are advancing individualized neoantigen therapy (INT) to train patients' immune systems against tumor-specific neoantigens using mRNA. This partnership underscores the industry shift toward 'one medicine for one patient' strategies, leveraging the unique genetic fingerprint of each tumor to guide clinical development.
mRNA therapeutics are transitioning from transient anti-viral vaccines into precise cancer immunotherapies capable of orchestrating potent antigen-specific T-cell and humoral responses. However, therapeutic resistance within immunologically "cold" tumors remains a formidable barr…
Follow-up data from the phase 2b KEYNOTE-942 trial shows that BioNTech’s mRNA-4157 combined with pembrolizumab reduced the risk of recurrence or death by 49% in high-risk stage III/IV melanoma patients compared to pembrolizumab alone. The combination also cut the risk of distant metastases or death by 62% at a median follow-up of three years. These results support the clinical benefit of personalized neoantigen mRNA vaccines in adjuvant settings.
West China Hospital is conducting a Phase I, single-arm dose-escalation study (NCT07724106) for NeoOVSV, an mRNA-lipid nanoparticle vaccine in stage II/III ovarian cancer. The trial evaluates safety and immunogenicity when the vaccine is administered alongside standard adjuvant chemotherapy and a PD-1 antibody. This represents an early-stage clinical evaluation of an mRNA platform in combination with checkpoint inhibition.
A recent review in Signal Transduction and Targeted Therapy highlights the clinical translation of personalized mRNA vaccines, citing Moderna’s mRNA-4157 and BioNTech’s autogene cevumeran for reducing recurrence risk. The article contrasts these advances with the historical limitations of therapeutic cancer vaccines, noting Sipuleucel-T as the sole FDA-approved example to date. It outlines various vaccine platforms and the immunological challenges remaining in the field.
The nonsense-mediated mRNA decay (NMD) is a highly conserved post-transcriptional mRNA screening system that is vital in keeping cellular integrity by targeting aberrant mRNAs harboring premature termination codons (PTCs) for degradation. Although traditionally considered as a sy…
Personalized mRNA neoantigen vaccines demonstrate great potential in cancer therapy, but their customization typically requires more than three months, risking the loss of the optimal therapeutic window for patients. This delay is primarily due to the reliance of current mRNA vac…
Researchers developed a bivalent mRNA-LNP vaccine targeting AFP and GPC3 neoantigens for hepatocellular carcinoma (HCC). Using spleen-homing CL15H6 LNPs, the formulation achieved superior antigen presentation and co-stimulatory molecule expression on splenic dendritic cells compared to clinical standards. In mouse models, two doses provided complete prophylactic protection against HCC challenge, demonstrating high biosafety and potent cytotoxic T lymphocyte responses.
Personalized neoantigen vaccines are an emerging strategy for cancer immunotherapy, but their effectiveness depends on selecting tumor-specific antigens capable of inducing functional T-cell responses. The VACINUS AI-informed neoantigen prioritization framework previously identif…
The preprint introduces k4neo, a k-mer indexing algorithm that computes tumor specificity of transcript variants by screening against 18,960 healthy tissue samples without mapping or re-analysis. This method addresses the computational cost of verifying tumor-restricted expression for mRNA targets like gene fusions and splice junctions in low-mutational-burden tumors. Benchmarked across nine cohorts, it accurately classifies somatic variants and nominated a median of 4-80 tumor-specific targets per cohort.
West China Hospital has registered a Phase I, single-arm, open-label dose-escalation study for NeoOVIV in stage II/III ovarian cancer patients post-surgery. The personalized mRNA-lipid nanoparticle vaccine will be administered with standard adjuvant chemotherapy and a PD-1 antibody to evaluate safety, tolerability, immunogenicity, and preliminary clinical activity.
Researchers evaluated an individualized neoantigen mRNA vaccine in early-stage TNBC, a subtype with high recurrence risk and no standard targeted therapies. The study demonstrates the feasibility, safety, and immunogenicity of the approach, noting lasting T cell immunity in patients. These findings offer early clinical signals that tailored vaccination may improve long-term outcomes, though larger trials are needed to confirm efficacy.
pVACtools v6 introduces significant updates to its open-source neoantigen prediction suite, including pVACsplice for detecting tumor-specific cis-splicing mutations and pVACbind for noncanonical neoantigen sources. The update also features an improved pVACvector algorithm designed to increase DNA/mRNA vector vaccine design success rates with shorter runtimes. These enhancements address the growing need for robust computational prioritization as neoantigen-based vaccines advance into later-stage trials.
The Bull Case For Moderna (MRNA) Could Change Following New Data On Its Personalized Cancer Vaccine simplywall.st